Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Published:2022-09-15 Issue:6 Volume:6 Page:859-870
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Baharnoori Moogeh,Bhan Virender,Clift Fraser,Thomas Kimberly,Mouallif Soukaïna,Adlard Nicholas,Cooney Philip,Blanchette François,Patel Barkha P.,Grima Daniel

Funder

Novartis Pharmaceuticals Canada

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-022-00363-1.pdf

Reference44 articles.

1. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.

2. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6(2):91–8.

3. Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, et al. Treatment optimization in multiple sclerosis: Canadian MS working group recommendations. Can J Neurol Sci. 2020;47(4):437–55.

4. Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Haring DA, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10(6):495–507.

5. Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Haring DA, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255–74.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review;Health Economics Review;2024-02-16

2. Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada;Journal of Comparative Effectiveness Research;2023-09

3. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment;Neurology and Therapy;2023-07-14

4. Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-07

5. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis;Expert Review of Neurotherapeutics;2023-05-04